

ALSGD
EURONEXT
GROWTH



**Bolster orthopedic surgery robotics
with radiation free real-time guidance**

SpineGuard®

April 2021

DSG = Dynamic Surgical Guidance

Pierre JÉRÔME
*Co-founder,
CEO & Chairman*



28 years in medtech
(EU/US)
S&M, Bus Dev, GM
Medtronic Sofamor Danek,
Boston Scientific, SpineVision
MBA from INSEEC
Bordeaux, France



30 years in finance, M&A
and strategic planning
17 in life sciences
(Dade-Behring, ev3)
MBA from Normandy
School of Management



Manuel LANFOSSI
Chief Financial Officer

**Company's
Leadership**

24 years in spine
(EU & US)
R&D, Operations, GM
Medtronic Sofamor Danek,
SpineVision (co-founder)
Master degree in
Mechanical Engineering
(ENSAM), Biomechanics
Post-graduate



Stéphane BETTE
*Co-founder &
Deputy CEO*

Co-invented DSG &
Electro-Conductive Shock
Wave Lithotripsy
Extensive experience in
R&D, international
marketing & business
development in medtech




Maurice BOURLION
NED and SAB Member

Led investment in over 15
health tech startups
Founding CEO of Ibionext:
specialized in financing
medical technologies from
creation to growth
Formerly Sofinnova &
Omnes



Alexia PEROUSE
*NED &
Initial Investment lead*

Navigation is not sufficient ...




... direct real time information is essential!

Introducing



DSG: Dynamic Surgical Guidance



Powerful radiation-free real time sensing technology

SpineGuard's Fundamentals




Unique Positioning

Dedicated to the deployment of DSG® in a broad spectrum of skeletal applications from drilling probes to automated implant placement.

Bring value to all stakeholders by perfectly matching market requirements: safety, X-ray reduction, efficiency, simplicity, ambulatory, AI and data analytics.

Strong Foundations



Uniquely positioned to provide game changing differentiation in robotic skeletal surgery

DSG Technology Deployment Since Inception




Integration of AI & digital features

2020



DSG Connect



Surgical Robotics

First partnerships

2017



Smart Screw



Dental

“DSG inside” strategic inflection

2015

IPO



2013



PediGuard smart drilling probes
addressing 1,6 million annual spinal procedures ww*

Foundation in
France / USA

2009

*: William Blair, Spine Technology Summit, I-DATA, AAOS 2017 Annual Report

DSG Brings Solutions To All Stakeholders



A compelling value proposition for the entire healthcare system



PATIENTS

- Minimized risk of neurological and vascular perforations
- Reduced radiation exposure
- Less infections



SURGEONS

- Reduced radiation exposure
- Operator in complete control
- Teaching tool
- Time efficiency



HOSPITALS


- No heavy equipment
- Less patient litigation
- Decreased financial risk
- No maintenance or sterilization

DSG Scientific Evidence


16 Peer-Reviewed Publications



Screw placement accuracy & breach detection



Radiation safety & surgical efficiency



Surgical education



*: vs 95% for 3D Navigation
Source: Mason 2014, Shin 2012


Commercialization Overview



Commercial partners in 30+ countries

- Agents in the US and France – 85% of revenue
- Distributors elsewhere
- Meta agents in Latin America and Middle East

Regulatory clearance and strong KOL support in all the main geographies



- Direct
- Significant
- In development

DSG Connect: Signal Visualization and Digital Capabilities



- ❑ CE marked (April 2020), FDA cleared (Feb. 2021)
- ❑ Boost the PediGuard business
- ❑ Feed R&D pipeline with DSG data



Modified electronic board
with wireless transmission



DSG connect
Software for tablet

Surgical Robotics A Perfect Match For DSG



\$4.3B surgical robots market growing ~ 10.5% annually*

In orthopedics, the robots have become a key driver of a >\$50B market**

Medtronic

MC: \$160B


Mazor



J&J

MC: \$420B

Velys



Nuvasive

MC: \$3,3B

Pulse



Stryker

MC: \$90B

Mako/Cardant



Yet all systems lack safety redundancy and real time sensing

Globus

MC: \$6,2B

Excelsius



ZB

MC: \$34B

Rosa



Tinavi

MC: \$2B

Ti Robot



Curexo

MC: \$238M

Robodoc




*: Zion Market Research (2019)

**: The Orthopedic Industry Market Report (2021)

DSG Surgical Robotics Program




- ❑ Company's Long Time Vision
- ❑ A 3-year partnership with Sorbonne University
- ❑ Collaboration to the Faros project



Proof of concept
First patent



Best 2019 paper award at
Hamlyn medical robotic conference



Artificial intelligence
Automated breach detection

Faros EU funding with
prestigious universities


New patents

Automated Smart
Screw placement

Bone cutting and
other applications



DSG Smart Universal Drill



□ A step forward in Spine

□ Opens the rest of Orthopedics



- ✓ DSG sensor embedded
- ✓ Integrated AI for breach prevention
- ✓ Universal usage
 - Free hand
 - Navigation & robot ready

Concept &
Specifications

Prototype &
Partnership

Design Freeze
& Scale-up

Regulatory
& Pre-launch

Full Launch
CE and USA

2020

2021

2022

2023

2024

Dental Implantology A Promising Partnership



DSG embedded into a dental drill: 8 million annual surgeries opportunity*

Partnership with
Adin / ConfiDent



Scientific abstracts

2nd gen. product

Live surgeries at
IDS Congress

DSG add-on to
dentistry power drill

2017


2018

2019

2021

CE Mark for SafeGuard

US Commercial



*: sinus avoidance, alveolar nerve avoidance, zygomatic implant fixation

Two other Pearls with Tremendous Clinical Potential



**BONE QUALITY
MEASUREMENT**



**Address the aging
population market**

2 patent applications

**Huge opportunity
in osteoporosis**



**ULTRASOUND
BASED
NAVIGATION**

**Full X-Ray Free
Guidance solution**

2 patent applications

Great synergy with DSG

Seeking partnerships to accelerate these projects

Financial Highlights



Operations

- Close to breakeven
- High gross margin
- Profitable US subsidiary
- Collective financial discipline



Balance Sheet

- Debt restructuring thanks to Chapter 11
- Best in class working cap
- Low capital intensity

Financial Results 2020 & Sales Q1 2021



<i>In thousand € – IFRS</i>	2020	2019
Sales	4 851	6 829
Gross Margin	4 037	5 768
<i>% of sales</i>	<i>83.2 %</i>	<i>86.5 %</i>
Sales, distribution & Marketing	2 578	3 500
Administration	1 740	1 855
R&D	680	725
Operating Result	- 961	- 311
<i>Other Operating Expenses</i>	<i>-875</i>	<i>-120</i>
Financial Result	-843	-643
Net Income / (Loss)	-2 716	-685
EBITDA	-1 284	-50

Cash as of 31 March 2021: €2.3M

Sales Q1-2021: €1,049K

The Covid-19 pandemic significantly impacted business
The company maintained R&D investment & expenses
Net Income positive US operations for the third consecutive year

Exit of the French sauvegarde and chapter 11



- **Validation of the French 'sauvegarde' plan** by the Commercial Court on March 24
- **Exit of the 'sauvegarde' proceeding:** roll-out of the execution phase
- **Exit of Chapter 11** should occur within a couple of months

Total liabilities of c. €5M including €4.8M of financial debt:

- ✓ Agreement with the bondholders (Norgine & Harbert) as part of the U.S. Chapter 11 proceeding for an amount of €3,875K with a 5-year reimbursement schedule starting February 2021;
- ✓ Bpifrance has accepted the reimbursement of its €975K loan over a 9-year period starting February 2022;
- ✓ The majority of the other creditors accepted a 9-year reimbursement plan starting February 2022 for a total of €60k;
- ✓ The few remaining suppliers opted for a one-time payment of €5K totaling €60K;
- ✓ There is no remaining litigation. Two non-material disputes have been addressed and resolved by the 'Mandataire Judiciaire' (French Trustee) on March 24, 2021.

**We exited the very challenging 2020 financially stronger
with a clear roadmap for 2021 and beyond**

Equity Line of €10M



- Amount: €10M over 36 months maximum with Nice & Green
- Possibility to differ or accelerate draws upon mutual agreement
- Draws: €1M each 65 stock days maximum or when market transactions exceed €10M after previous draw
- Conversion: 93% of the lowest VWAP 10 days prior to conversion
- Profit sharing program: as a % of net gains realized by N&G

Selective investments while remaining close to breakeven

Road Map For Shareholder Value Creation



- ❖ **Boost sales activities with the launch of DSG Connect**
- ❖ **Accelerate the implementation of DSG in ortho-robotics**
- ❖ **Co-develop a dental drill embedding DSG with ConfiDent**
- ❖ **Initiate new strategic partnerships**

**Further reveal the tremendous potential of DSG
in the ~\$50B* orthopedic market**